Therefore, SLFN11 could be a prevalent biomarker for RRM1 or PARP inhibitors developed as molecular targeted therapies for SCLC, in addition to and independently of BRCA1/2 mutation and homologous recombination DNA pathway deficiency in pre-clinical models. The gene discussed is SLFN11; the disease is small cell lung carcinoma.